Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BeOne Medicines Ltd.ONC · Entity 2168 | President, Global Head of R&D | June 23, 2026 | June 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BeOne Medicines Ltd.
Report date June 23, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-06-23 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-06-23 · Sale · Disposed 1,068 · Balance 0 F5: Each American Depositary Share represents 13 Ordinary Shares. F6: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 1,681,004 |
Reported balance
Holding disclosure · report date 2026-06-23 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,681,004 |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 601,965 |
Reported balance
Holding disclosure · report date 2026-06-23 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 601,965 F1: These securities are held by Wang Holdings LLC, the limited liability company interests of which are owned by the Reporting Person, his spouse and a trust created by the Reporting Person for the benefit of his spouse and children, for which the Reporting Person disclaims beneficial ownership. |
| RMB SharesSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
Holding disclosure · report date 2026-06-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 0 F2: The term "RMB Shares" is used herein to represent the ordinary shares, par value $0.0001 per share, of the Issuer, issued directly by the Issuer in the Issuer's initial public offering on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange (the "STAR Offering"), to permitted investors in Renminbi ("RMB") within the People's Republic of China ("PRC") in accordance with the rules of the STAR Market. F3: The Issuer established an employee participation program ("RMB Shares Employee Participation Plan"), which allows certain executive officers and qualified employees of the Issuer's subsidiaries in the PRC to indirectly participate in the STAR Offering and purchase certain RMB Shares from the Issuer through an asset management plan administrated by China International Capital Corporation Limited in a transaction that is exempt under Rule 16b-3. The RMB Share Employee Participation Plan purchased an aggregate of 2,069,546 RMB Shares directly from the Issuer in the STAR Offering at the initial public offering price of RMB192.6 per RMB Share (or $30.1295 based on an assumed exchange rate of $1.00 = RMB6.3924). F4: The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, has contributed RMB10 million to the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are held by Wang Holdings LLC, the limited liability company interests of which are owned by the Reporting Person, his spouse and a trust created by the Reporting Person for the benefit of his spouse and children, for which the Reporting Person disclaims beneficial ownership.
F2: The term "RMB Shares" is used herein to represent the ordinary shares, par value $0.0001 per share, of the Issuer, issued directly by the Issuer in the Issuer's initial public offering on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange (the "STAR Offering"), to permitted investors in Renminbi ("RMB") within the People's Republic of China ("PRC") in accordance with the rules of the STAR Market.
F3: The Issuer established an employee participation program ("RMB Shares Employee Participation Plan"), which allows certain executive officers and qualified employees of the Issuer's subsidiaries in the PRC to indirectly participate in the STAR Offering and purchase certain RMB Shares from the Issuer through an asset management plan administrated by China International Capital Corporation Limited in a transaction that is exempt under Rule 16b-3. The RMB Share Employee Participation Plan purchased an aggregate of 2,069,546 RMB Shares directly from the Issuer in the STAR Offering at the initial public offering price of RMB192.6 per RMB Share (or $30.1295 based on an assumed exchange rate of $1.00 = RMB6.3924).
F4: The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, has contributed RMB10 million to the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose.
F5: Each American Depositary Share represents 13 Ordinary Shares.
F6: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 07, 2023 Filed Jun 9, 2023 21:46 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 74 | $223.23 | $16,519.26 |
DisclosureSEC source: 0001651308-23-000079 · wf-form4_168634717636068.xml · nonDerivative · entry 4 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 388 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2019, subject to continued service. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.625 to $223.53, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 21:32 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 458 | $177.32 | $81,214.71 |
DisclosureSEC source: 0001651308-22-000115 · wf-form4_165645195007556.xml · nonDerivative · entry 4 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 26, 2018, subject to continued service. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 21:40 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 707,876 | $0.00 Strike: $11.98 | $0.00 |
DisclosureSEC source: 0001651308-22-000113 · wf-form4_165610680385112.xml · derivative · entry 4 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 707,876 Underlying: Ordinary Shares · 707,876 shares Expires 2032-06-21 F6 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F6 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F7 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of June 22, 2022 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 21:40 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 125,255 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-22-000113 · wf-form4_165610680385112.xml · nonDerivative · entry 1 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,509,989 F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Read SEC document |
| June 21, 2022 Filed Jun 22, 2022 21:47 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 723 | $149.01 | $107,733.65 |
DisclosureSEC source: 0001651308-22-000091 · wf-form4_165593443190424.xml · nonDerivative · entry 5 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F8 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 17, 2020, subject to continued service. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.0002 to $149.065, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 21:47 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 445 | $139.40 | $62,033.76 |
DisclosureSEC source: 0001651308-22-000091 · wf-form4_165593443190424.xml · nonDerivative · entry 4 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 723 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 16, 2021, subject to continued service. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.388 to $139.418, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 21:43 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 660 | $142.00 | $93,717.56 |
DisclosureSEC source: 0001651308-22-000080 · wf-form4_165472461482334.xml · nonDerivative · entry 4 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2019, subject to continued service. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.91 to $142.13, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| May 17, 2022 Filed May 19, 2022 20:39 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 999,999 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0001651308-22-000072 · wf-form4_165299277795291.xml · derivative · entry 6 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 999,999 shares Expires 2027-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested on June 30, 2021. Read SEC document |
| May 17, 2022 Filed May 19, 2022 20:39 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 233,948 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001651308-22-000072 · wf-form4_165299277795291.xml · derivative · entry 5 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 233,948 shares Expires 2026-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested on July 31, 2020. Read SEC document |
| May 17, 2022 Filed May 19, 2022 20:39 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionOrdinary Shares | 999,999 | $3.49 | $3,489,996.51 |
DisclosureSEC source: 0001651308-22-000072 · wf-form4_165299277795291.xml · nonDerivative · entry 2 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,408,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2022 Filed May 19, 2022 20:39 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionOrdinary Shares | 233,948 | $2.29 | $535,740.92 |
DisclosureSEC source: 0001651308-22-000072 · wf-form4_165299277795291.xml · nonDerivative · entry 1 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 408,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 22:05 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantRMB Shares | 0 | $30.13 | $0.00 |
DisclosureSEC source: 0001651308-21-000263 · wf-form4_163977871142348.xml · nonDerivative · entry 4 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F5 · security: The term "RMB Shares" is used herein to represent the ordinary shares, par value $0.0001 per share, of the Issuer, issued directly by the Issuer in the Issuer's initial public offering on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange (the "STAR Offering"), to permitted investors in Renminbi ("RMB") within the People's Republic of China ("PRC") in accordance with the rules of the STAR Market. F6 · kind: The Issuer established an employee participation program ("RMB Shares Employee Participation Plan"), which allows certain executive officers and qualified employees of the Issuer's subsidiaries in the PRC to indirectly participate in the STAR Offering and purchase certain RMB Shares from the Issuer through an asset management plan administrated by China International Capital Corporation Limited in a transaction that is exempt under Rule 16b-3. The RMB Share Employee Participation Plan purchased an aggregate of 2,069,546 RMB Shares directly from the Issuer in the STAR Offering at the initial public offering price of RMB192.6 per RMB Share (or $30.1295 based on an assumed exchange rate of $1.00 = RMB6.3924). F7 · kind: The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, has contributed RMB10 million to the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose. F6 · shares: The Issuer established an employee participation program ("RMB Shares Employee Participation Plan"), which allows certain executive officers and qualified employees of the Issuer's subsidiaries in the PRC to indirectly participate in the STAR Offering and purchase certain RMB Shares from the Issuer through an asset management plan administrated by China International Capital Corporation Limited in a transaction that is exempt under Rule 16b-3. The RMB Share Employee Participation Plan purchased an aggregate of 2,069,546 RMB Shares directly from the Issuer in the STAR Offering at the initial public offering price of RMB192.6 per RMB Share (or $30.1295 based on an assumed exchange rate of $1.00 = RMB6.3924). F7 · shares: The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, has contributed RMB10 million to the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose. F6 · acquired: The Issuer established an employee participation program ("RMB Shares Employee Participation Plan"), which allows certain executive officers and qualified employees of the Issuer's subsidiaries in the PRC to indirectly participate in the STAR Offering and purchase certain RMB Shares from the Issuer through an asset management plan administrated by China International Capital Corporation Limited in a transaction that is exempt under Rule 16b-3. The RMB Share Employee Participation Plan purchased an aggregate of 2,069,546 RMB Shares directly from the Issuer in the STAR Offering at the initial public offering price of RMB192.6 per RMB Share (or $30.1295 based on an assumed exchange rate of $1.00 = RMB6.3924). F7 · acquired: The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, has contributed RMB10 million to the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose. F6 · balance_after: The Issuer established an employee participation program ("RMB Shares Employee Participation Plan"), which allows certain executive officers and qualified employees of the Issuer's subsidiaries in the PRC to indirectly participate in the STAR Offering and purchase certain RMB Shares from the Issuer through an asset management plan administrated by China International Capital Corporation Limited in a transaction that is exempt under Rule 16b-3. The RMB Share Employee Participation Plan purchased an aggregate of 2,069,546 RMB Shares directly from the Issuer in the STAR Offering at the initial public offering price of RMB192.6 per RMB Share (or $30.1295 based on an assumed exchange rate of $1.00 = RMB6.3924). F7 · balance_after: The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, has contributed RMB10 million to the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose. F7 · ownership.nature: The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, has contributed RMB10 million to the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose. Read SEC document |
| October 31, 2021 Filed Dec 17, 2021 22:05 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GiftOrdinary Shares | 58,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-21-000263 · wf-form4_163977871142348.xml · nonDerivative · entry 3 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 58,188 F4 · ownership.nature: These securities are held by Wang Holdings LLC, the limited liability company interests of which are owned by the Reporting Person, his spouse and a trust created by the Reporting Person for the benefit of his spouse and children, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| October 31, 2021 Filed Dec 17, 2021 22:05 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GiftOrdinary Shares | 58,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-21-000263 · wf-form4_163977871142348.xml · nonDerivative · entry 2 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F2 · kind: Bona fide gift of the limited liability company interest which is exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16b-5. F3 · ownership.nature: These securities are held by Wang Holdings LLC, which is owned by the Reporting Person and his spouse. Read SEC document |
| September 28, 2021 Filed Dec 17, 2021 22:05 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GiftOrdinary Shares | 58,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-21-000263 · wf-form4_163977871142348.xml · nonDerivative · entry 1 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,551 F1 · kind: This is a capital contribution by the Reporting Person to Wang Holdings LLC, which is owned by the Reporting Person and his spouse. Bona fide gift of shares which is exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16b-5. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 20:48 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 455 | $362.48 | $164,929.95 |
DisclosureSEC source: 0001651308-21-000139 · wf-form4_162508606172808.xml · nonDerivative · entry 2 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 26, 2018, subject to continued service. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $362.331 to $362.82, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 20:47 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 802 | $331.15 | $265,583.18 |
DisclosureSEC source: 0001651308-21-000127 · wf-form4_162430843229244.xml · nonDerivative · entry 2 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 17, 2020, subject to continued service. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $330.78 to $331.62, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:47 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 332,527 | $0.00 Strike: $26.53 | $0.00 |
DisclosureSEC source: 0001651308-21-000127 · wf-form4_162430843229244.xml · derivative · entry 3 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,527 Underlying: Ordinary Shares · 332,527 shares Expires 2031-06-15 F5 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. F5 · shares: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. F6 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on June 16, 2022, and the remaining in 36 successive equal monthly installments, subject to continued service. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:47 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 53,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-21-000127 · wf-form4_162430843229244.xml · nonDerivative · entry 1 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,654 F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 16, 2021, subject to continued service. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:46 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 656 | $354.26 | $232,392.33 |
DisclosureSEC source: 0001651308-21-000108 · wf-form4_162327158340350.xml · nonDerivative · entry 2 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2019, subject to continued service. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $353.646 to $354.54, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.